Thiago Moreno L. Souza

TL;DR: It is demonstrated that increased platelet activation and platelet-monocyte aggregate formation are observed in severe COVID-19 patients, but not in patients presenting mild CO VID-19 syndrome, and these data shed light on new pathological mechanisms involving plateletactivation and Platelet-dependent monocyte TF expression, which were associated with COVID -19 severity and mortality.

TL;DR: It is found that ZIKV circulated undetected in multiple regions for many months before the first locally transmitted cases were confirmed, highlighting the importance of surveillance of viral infections.

TL;DR: The overall theoretical analysis of the molecular descriptors of 2a, 2d and 2g revealed that their HOMO energy is similar to other antivirals in use and together with the volume may contribute for the biological profile as they may allow new interactions with the target.

TL;DR: Sofosbuvir inhibited ZIKV replication in different cellular systems, such as hepatoma (Huh-7) cells, neuroblastoma (SH-Sy5y), neural stem cells (NSC) and brain organoids, and induced an increase in A-to-G mutations in the viral genome, highlighting a potential secondary use of sofosBuvir, an anti-HCV drug, against ZikV.

TL;DR: In this paper, the authors show that SARS-CoV-2 engages inflammasome and triggers pyroptosis in human monocytes, experimentally infected, and from patients under intensive care.